Accessibility statement

Cizzle Biotechnology Limited continues to develop

Posted on 17 September 2021

The University of York is to collaborate with diagnostics development specialists Cizzle Biotechnology to develop a blood test to detect lung cancer.

Image courtesy of the National Cancer Institute via

Cizzle Biotechnology started life at the University, having been based on research and development undertaken in laboratories here, under the direction of Professor Dawn Coverley. The University ‘spin-out’ company was the first at York to be listed on the London Stock Exchange earlier this year.


This new agreement will see that relationship develop, with the provision of seconded staff and laboratory access to support reagent generation work in collaboration with Cizzle’s new Contract Research Organisation (CRO) partner Fairjouney Biologics.

Professor Coverley said: “I’m delighted that Cizzle’s relationship with the University of York will continue. It is a world-class research institution and it’s fitting that having started life here, Cizzle will be able to continue developing with the University.”


Allan Syms, Executive Chairman of Cizzle Biotechnology, said: “We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world’s premier institutions for inspirational and life-changing research.

“This new agreement will provide valuable additional resources and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer.”